danshenol A

Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research[1][2][3][4].

Research Areas >> Cancer

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Metabolic Enzyme/Protease >> Aldose Reductase

Research Areas >> Inflammation/Immunology

IC50: 0.1 μM (Aldose reductase)[3]

Danshenol A (10 nM; pretreatment for 1 h) 单独处理显示对 ICAM-1 在 mRNA 和蛋白质水平的表达没有影响。Danshenol A 显着逆转 TNF-α 诱导的 ICAM-1 表达和随后的单核细胞粘附，以及升高的活性氧 (ROS) 生成和 NOX4 表达[1]. Danshenol A 通过 NOX4 依赖性 IKKβ/NF-κB 通路抑制 TNF-α 诱导的 ICAM-1 表达和随后的单核细胞与内皮细胞的粘附[1]。 Danshenol A (1, 3, and 10 μM; pretreated for 35 min) 恢复血管紧张素 II 诱导的心肌细胞凋亡。此外，Danshenol A 抑制心肌细胞线粒体氧化还原信号通路[2]。 Danshenol A 抑制 K562 (IC50 = 0.53 μg/mL)、T-24 (IC50 = 7.94 μg/mL)、QGY (IC50 = 4.65 μg/mL) 和 Me180 (IC50 = 6.89 μg/mL) 细胞系的活性[4]。 Western Blot Analysis[1] Cell Line: HUVEC cells Concentration: 10 nM Incubation Time: Pretreatment for 1 h Result: Showed no effect on the ICAM-1 expression at both mRNA and protein levels.

Danshenol A (0.3-3mg/kg；口服；每天一次；持续 12 周) 改善 SHR 大鼠的血压、心脏损伤和心肌胶原体积，并改善心功能。Danshenol A 修复线粒体结构/功能，减轻心肌氧化应激[2]。 Animal Model: Forty male spontaneously hypertensive rats (SHR) and eight male Wistar-Kyoto (WKY) rats at the age of 16 weeks[2] Dosage: 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration: Orally administration; daily; for 12 weeks Result: Ameliorated blood pressure, cardiac injury, and myocardial collagen volume and improved cardiac function.

[1]. Wenwen Zhao, et al. Danshenol A inhibits TNF-α-induced expression of intercellular adhesion molecule-1 (ICAM-1) mediated by NOX4 in endothelial cells. Sci Rep. 2017 Oct 11;7(1):12953.  

[2]. Kai Chen, et al. Danshenol A Alleviates Hypertension-Induced Cardiac Remodeling by Ameliorating Mitochondrial Dysfunction and Suppressing Reactive Oxygen Species Production. Oxid Med Cell Longev. 2019 Sep 11;2019:2580409.  

[3]. Y Tezuka, et al. Aldose reductase inhibitory constituents of the root of Salvia miltiorhiza Bunge. Chem Pharm Bull (Tokyo). 1997 Aug;45(8):1306-11.  

[4]. Gang Xu, et al. Two new abietane diterpenoids from Salvia yunnanensis. Planta Med. 2006 Jan;72(1):84-6.